Comparison of common transfection agents for
Lipid nanoparticles (LNP) are invaluable carriers for drug and gene delivery, and they are classified as cationic, neutral and anionic depending on the electronic charges existing on the surface of the vesicles . These charges are originated from the charged lipids from which lipid nanoparticles are formulated. Cationic LNP are commonly used for DNA or RNA carriers due to their interaction with negatively-charged nucleotide. Both neutral and negatively-charged LNPs are used for drug delivery  and may be formulated as sterically stable LNPs (SSLNPs), which are amendable for cell type-specific or tissue-specific targeting delivery . For liver drug delivery, tremendous efforts have been made to develop cell type-selective lipid-based drug carriers. Effective approaches in targeting hepatocytes, Kupffer cells and hepatic stellate cells have been evaluated in small animals [3, 4], and some of them may be translational to clinical application . These approaches are referable when cationic LNPs are considered for cell type-selective gene delivery. A prerequisite for the success of gene therapy for liver disorders is the development of powerful gene carriers. Non-viral vectors have been very successful for gene transfer in an
There are a number of critical components for a potential gene therapy product to move from one step to the next in this pipeline. Promisingly, LNP-mediated gene transfection for the treatment of genetic and metabolic disorders or tumors has been moved to clinical trial phases (http://clinicaltrials.gov). A phase I pilot study of gene therapy for cystic fibrosis using cationic liposome-mediated gene transfer (NCT00004471) has been completed. A phase I trial of intratumoral epidermal growth factor receptor (EGFR) antisense DNA delivered by DC-Chol liposomes in advanced head and neck cancer, including oral squamous cell carcinoma (NCT00009841) and DOTAP-Chol-Fus1 liposome-mediated gene therapy for non-small cell lung cancer (NCT00059605]  were conducted respectively by University of Pittsburg and MD Anderson Cancer Center in collaboration with the National Cancer Institute (NCI). Fus1 is a tumor suppressive gene that has been shown to be effective in suppressing the growth of original or metastatic lesions of non-small lung cancer when it is delivered locally or systemically . Thus, it appears that genetic therapy using LNPs as gene carriers has the potential to be specially tailored for genetic disorders or cancers.
2. Nanoparticle carriers for drug or gene delivery
Lipid-based gene carriers include liposomes (cationic or anionic), polymer and dendrimer nanoparticles. Cationic liposomes are capable of delivering genes to cells or tissues, and achieving maximal therapeutic efficiency with minimal adverse effects . However, the use of cationic LNPs for
Polymeric non-viral vectors have exhibited additional advantages of lower toxicity and immunogenicity [21, 22]. These vectors may offer the possibility of industrial production following good manufacturing practice (GMP). Amphiphilic polyethylene glycol (PEG) has been engineered as a linker, most for coupling peptides to cationic lipids. Other polymers, such as dendritic poly(L-lysine)-b-poly(L-lactide)-b-dendritic vector , poly (ethyleneimine) (PEI) , poly (methacrylate)  and polyamidoamine dendrimers , have been demonstrated to be effective for
3. Liver-specific gene delivery
Because of our interest in gene therapy of liver disorders, we have focused our efforts on improving liver-based gene delivery. The pathogenesis of liver injury and fibrosis involves complicated interactions among different cell populations in the liver, soluble factors, such as cytokines and reactive oxygen species (ROS), and the extracellular matrix components. In order to improve the efficacy in preventing hepatocellular injury, the use of LNPs that are capable of delivering hepatoprotective agents to the liver, selectively to hepatocytes, will increase local concentration of therapeutic agents, reduce adverse effects, and achieve maximal therapeutic efficiency. The parenchymal cell type in the liver is hepatocytes, which are responsible for an array of metabolic function in the body and are often damaged in a variety of pathological processes. The asialoglycoprotein receptor (ASGP-R) on mammalian hepatocytes provides a unique means for the development of liver-specific drug or gene carriers. The abundant receptors on hepatocytes specifically recognize the natural ligands, lectin and asialofetuin (AF), as well as those with terminal galactose or N-acetylgalactosamine residues, and hepatocytes endocytose these ligands for an intracellular degradation process [27, 28]. The use of its natural or synthetic ligands, such as galactosylated cholesterol, glycolipids or galactosylated polymers to label LNPs has achieved significant targeting efficacy to the liver [4, 28]. AF-labeled LNPs have been used for improving liver-targeting gene transfer in small animals , yet there have not been successful reports available in the translation to large animals, such as pigs . Instead, plasmid DNA was directly administrated into the hepatic vein through a catheter with a balloon closure of hepatic vein blood flow . One particular attention has been drawn in terms of the use of AF-labeled drug carriers for HCC targeting. The expression of ASGP-R in HCC cells varies depending on the differentiation status of HCC cells . In general, well-differentiated HCC usually expresses relatively high levels of hepatocyte-specific genes, including ASGP-R; whereas poorly-differentiated HCC expresses minimal or no hepatocyte-specific genes, including ASGP-R . In most cases, there exists the dramatic heterogeneity of liver-specific gene expression in human HCC tissues , and decreased expression of ASGP-R was observed in liver cancer tissue . Therefore, using AF or other galactosylated or lactosylated residues to label LNPs for drug or gene delivery may not always be effective for patients with HCC, because HCC develops on a variety of disease backgrounds and there is a striking variation in ASGP-R expression levels in HCC from different patients. Using well-differentiated hepatoma cells, such as HepG2, Hep3B and Huh-7 cells, as an
High density lipoprotein (HDL) has a high drug carry capacity, and can be recognized by HDL receptors on hepatocytes. Recombinant HDL was utilized to deliver an anti-HBV peptide (nosiheptide) to the liver, and it was shown to achieve a selective distribution in hepatoma cells
Given the fact that hepatic stellate cells (HSCs) are the major cell type responsible for hepatic fibrosis, a repairing process that causes excess production of extracellular matrix components and deposition of fibrotic scaring in chronically injured liver , much attention has been focused on targeting this cell type in the last decade. A couple of cell surface molecules that are overexpressed on activated HSCs during hepatic fibrogenesis, such as insulin growth factor receptor II , collagen type VI and platelet-derived growth factor (PDGF) receptor β-subunit  are selected as the cell surface targets. Drug carriers labeled with specific peptides recognizing these cell surface molecules, such as cyclic peptide containing arginine-glycine-aspartate (RGD)-labeled sterical lipid nanoparticles  or Mannose-6-phosphate human serum albumin (M6P/HAS)  exhibited HSC-selective distribution. The RGD cyclic peptide was recently used as a targeting molecule for the recognition of activated HSCs in two animal models for early diagnosis of hepatic fibrosis with a SPECT imaging modality . Using the retinol binding protein (RBP) in activated HSCs seems to be very effective in delivering siRNA against gp46 (rat homolog of human heat shock protein 47), and inhibiting fibrosis in two animal models .
Targeting approaches for drug or gene delivery to other non-parenchymal cell types, such as Kupffer cells or sinusoidal endothelial cells, are summarized recently . These approaches are crucial in delivering agents which are anti-inflammatory or anti-oxidants to these cell types due to the fact that Kupffer cells are pivotal in the mediation of inflammatory responses and subsequent fibrogenesis .
4. Polylipid nanoparticle-mediated liver gene delivery
Compared to drug delivery, LNP-mediated
We also developed an approach to promote normal hepatocytes to proliferate
|Size changes(50%FBS)||Irrelevant||100±20nm||2206 ± 311 nm||1050±100 nm|
|Cytotoxicity (LDH release)||Low or none||Normal||10±3%
|Binding rate to serum protein||Low||Low||Obvious||20-30-fold higher than PLNP|
|Usage||Raw material for PLNP||
5. Preclinical trials for proof of the concept
In order to demonstrate that our PLNP formulation is effective in delivering functional genes to the liver, we established a liver injury model in mice caused by the treatment with D-galactosamine (D-Gal) and lipopolysaccharide (LPS). This combination of D-Gal/LPS treatment resulted in a profound acute liver injury characterized by massive liver cell death through apoptosis, elevation of serum alanine aminotransferase (ALT), significant oxidant stress, depletion of the reduced form of glutathione and enhanced lipid peroxidation . In separate studies we have demonstrated that anti-oxidant enzyme such as extracellular superoxide dismutase (EC-SOD), SOD mimetics (MnTBAP) and catalase are effective in the prevention of hepatic toxicity caused by xenobiotics in primary hepatocytes or hepatoma cells [51-53], and they improved recipient survival and graft function and growth after small-for-size liver transplantation in rats . Therefore, we chose the human EC-SOD gene as a functional gene to prove the feasibility. The EC-SOD gene product was exclusively secreted into the extracellular space and functions as an ROS scavenger. ROS are generated in both intracellular and extracellular spaces, and superoxide anions and hydrogen peroxide (H2O2) are able to cross the plasmatic membrane to enter the extracellular space . It was found that two days after portal vein injection of EC-SOD polyplexes, liver EC-SOD gene expression was increased approximately 50-fold compared to the group receiving injection of control plasmid polyplexes, and serum SOD activity was increased accordingly. On the other hand, serum ALT was reduced to nearly one third in mice receiving EC-SOD polyplex injection compared to those with D-Gal/LPS challenge, along with improved liver histology, restored glutathione levels and decreased lipid peroxidation . The findings of this preclinical trial confirmed the effectiveness of PLNP-mediated EC-SOD gene delivery to the liver, and that the delivery protected the mice from oxidant stress-associated liver injury. The results also indicate that this anti-oxidant gene delivery approach could be useful in attenuating xenobiotics or drug metabolite-induced toxicity to the liver.
Ischemia/reperfusion (I/R)-associated donor organ damage is inevitable in all solid organ transplantation, and is caused by enhanced oxidant stress with release of inflammatory cytokines, such as tumor growth factor-α (TNF-α) and interleukin 2 (IL-2). Although the precise molecular mechanism of the I/R-associated liver injury remains to be investigated, enhanced oxidant stress with release of superoxide anions or H2O2, depletion of the reduced form of glutathione and increased lipid peroxidation has been the key element in the pathogenesis in orthotopic liver transplantation (OLT) or small size liver graft transplantation (SSLGT) [54-56]. Thus, it is rational to use of antioxidant gene transfer to minimize oxidant stress and improve the donor organ quality and function after the implantation. We delivered either EC-SOD, catalase gene or in combination, using the same approach as described above. Two days after the delivery, the transgene expression was increased for 10-50-fold, with increased SOD or catalase activity in the mouse liver. This delivery led to a marked decrease in superoxide anion levels and H2O2 release along with a decrease in serum ALT levels, liver lipid peroxidation and dramatic improvement of liver histology . This study was positively commented by two well-known hepatologists from Europe as an editorial, quoting “beyond a proof of the principle, the study could be the basis for studies with larger animals and may help bridge the gap between the basic understanding of pathophysiologic processes in animal models towards a practical clinical application in liver transplantation” . The findings are especially applicable in living donor liver transplantation, for which small or margin donor livers were used for transplantation. Much more pronounced oxidant stress, a higher rate of graft failure, and retarded graft growth are found in small size liver transplantation than OLT [54, 58]. The margin grafts with small size or steatosis and fibrotic deposition are often used for transplantation in clinics due to severe shortage of donor organs.
6. Challenges in scaling-up and moving towards clinical applications
Our preclinical studies were performed in mice, and there are certainly a number of issues to face when this anti-oxidant gene therapy approach is considered to be evaluated in middle or large size animals such as rabbits, dogs, monkeys or pigs. The first issue is to scale-up, which includes the plasmid DNA generation, synthesis of PCL in a quantity, and formulation of PLNP at a volume sufficient enough for the use in large animals. More challenges exist regarding how to stimulate liver cells to proliferate in large animals and deliver polyplexes locally to the liver. Using a catheter through the femoral vein or jugular vein for retrograde administration into hepatic vein or passing into the portal vein for administration similar to the transjugular intrahepatic portosystemic shunt (TIPS) procedure, which is used to lower portal hypertension in cirrhotic patients, should be feasible in large animals when angiography and the administration are performed by an experienced specialist with the availability of angiographic devices. The latter method was used to administer adenoviral vector in baboons . One trial of plasmid DNA injection into the hepatic vein by blocking the hepatic vein out-flow with an inflated balloon achieved high gene expression levels in selected pig liver lobes . Safety concerns include amount of polyplexes to be administrated locally and the effects of the plasmid DNA, PLNP and polyplexes on the liver as well as systematically. LNP-mediated gene transfer is usually transient; therefore, there will be less concern for long-term effects of the transgene products on the host. However, immune reaction to human gene products in animals may occur if the transgene products are produced at sustained levels for a long period of time. It is preventable by administration of immunosuppressive agents, such as FK506. Moreover, innate immunity to plasmid DNA with bacterial unmethylated CG dinucleotide (CpG) can be eliminated by using CpG-free plasmid .
An additional concern is to establish a liver injury model to evaluate the effect of anti-oxidant gene transfer by PLNP in large animals. For pigs, exposure to a loading dose of 0.25 g/kg, maintaining the blood concentration of acetaminophen at 350-450 mg/dl, and adapting enteric maintenance dose of 1,000-3,000 mg/hour resulted in the onset of acute liver failure (prothrombin time value <30%) within 32±4.4 hours, and further mortality in 15.8±2.4 hours . A large dose of acetaminophen intake causes significant oxidant stress and acute liver injury due to its metabolism and generation of an interactive metabolite, n-acetyl-p-benzoquinone imine (NAPQI), which binds to the cytoplasmic membrane, leads to lipid peroxidation, depletion of antioxidants, such as glutathione, and results in hepatic injury. Not only will the delivery of antioxidant genes with PLNP in a pig model of liver injury assess the therapeutic efficacy, but also take advantage of a regenerative response to the injury for high transgene expression. Alternatively, small size graft liver transplantation (SSGLT) at ≤50% graft volume could be performed in rabbits or pigs to mimic living donor liver transplantation in humans. Significant oxidant stress-associated injury and regenerative response in the small size grafts will be the best fit for the high transgene expression and ROS scavenging property of the gene product. Therefore, SSGLT may be considered to be a valuable model for evaluating the feasibility and efficacy of anti-oxidant gene transfer for small-for-size-associated graft failure in a transplant setting.
In summary, moving promising PLNP-mediated antioxidant gene transfer from small animals to large animals may face more challenges than discussed above, and it is even more challenging when further considering for clinical use, in terms of safety concern and administrative approval. Fig. 3 provides a schematic illustration of the roadmap from bench to bedsides of a potential biological therapy. The reality is that with limited funding opportunities from governmental or private agencies, to cope with multi-facet challenges at a large scale, it is less likely to reach the final goal in a short term. Attracting financial investments and taking advantages of cutting-edging technologies and vast resources from biopharmaceutical companies may advance this process in a fast pace. In this context, the net benefits would be the early clinical application of this promising antioxidant gene transfer in patients with critical needs and the financial return from the investment. We would foresee such a movement occurring in the near future.
7. Conclusion and prospectives
Non-viral vector-mediated gene transfer has less concern in terms of integration-associated long-term transgene expression and insertion-induced mutation. In general, non-viral vector elicits minimal immune responses in contrast to adenoviral vectors . However, non-viral vectors, such as lipid nanoparticles (LNPs) possess their own drawbacks when they are considered for
AcknowledgmentsThe studies presented in the chapter were supported by the UC Davis Health System Award, American Liver Foundation Liver Scholar Award, UC Davis Technology Transfer Award, and the National Institute of Diabetes, Digestive and Kidney Diseases (DK069939) to JW. The commercialization and translation to clinical application of this technology is supported by the Nanjing Municipal Innovative Technology Award (321 Plan). Yahan Fan is the recipient of China Scholarship Council Award (201207610003).
Abbreviations used in the chapter
ASGP-R = asialoglycoprotein receptor; DOTAP = (dioleoyloxy)-3-(trimethylamonio) propane; DOPE = L-a dioleoyl phosphatidylethanolamine; EC-SOD = extracellular superoxide dismutase; HCC = hepatocellular carcinoma; LDLT = Living donor liver transplantation; LNP = lipid nanoparticles; OLT = orthotopic liver transplantation; PEG = polyethylene glycol; PLNP = polylipid nanoparticles; polyplex = PLNP-plasmid DNA complex; RES = reticuloendothelial system.
Wu J, Zern MA. Modification of liposomes for liver targeting. J Hepatol 1996;24:757-763.
Wu J, Wu GY, Zern MA. The prospects of hepatic drug delivery and gene therapy. Expert Opin Investig Drugs 1998;7:1795-1817.
Du SL, Pan H, Lu WY, Wang J, Wu J, Wang JY. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007;322:560-568.
Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998;27:772-778.
Abegunewardene N, Schmidt KH, Vosseler M, Kreitner KF, Schreiber LM, Lehr HA, Gori T, et al. Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. Clin Hemorheol Microcirc 2011;49:271-278.
Liu L, Zern MA, Lizarzaburu ME, Nantz MH, Wu J. Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Ther 2003;10:180-187.
Wu J, Lizarzaburu ME, Kurth MJ, Liu L, Wege H, Zern MA, Nantz MH. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjug Chem 2001;12:251-257.
Nyunt MT, Dicus CW, Cui YY, Yappert MC, Huser TR, Nantz MH, Wu J. Physico-chemical characterization of polylipid nanoparticles for gene delivery to the liver. Bioconjug Chem 2009;20:2047-2054.
Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 2012;7:e34833.
Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004;11:733-739.
Sakurai F, Nishioka T, Saito H, Baba T, Okuda A, Matsumoto O, Taga T, et al. Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid. Gene Ther 2001;8:677-686.
Fumoto S, Kawakami S, Shigeta K, Higuchi Y, Yamashita F, Hashida M. Interaction with blood components plays a crucial role in asialoglycoprotein receptor-mediated in vivo gene transfer by galactosylated lipoplex. J Pharmacol Exp Ther 2005;315:484-493.
Fumoto S, Kawakami S, Ito Y, Shigeta K, Yamashita F, Hashida M. Enhanced hepatocyte-selective in vivo gene expression by stabilized galactosylated liposome/plasmid DNA complex using sodium chloride for complex formation. Mol Ther 2004;10:719-729.
Liu Y, Mounkes LC, Liggitt HD, Brown CS, Solodin I, Heath TD, Debs RJ. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997;15:167-173.
Schleh C, Rothen-Rutishauser B, Kreyling WG. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Eur J Pharm Biopharm 2011;77:350-352.
Ramesh R, Ito I, Saito Y, Wu Z, Mhashikar AM, Wilson DR, Branch CD, et al. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol 2004;23:850-857.
Wu J, Hecker JG, Chiamvimonvat N. Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev 2009;61:351-363.
Wei M, Xu Y, Zou Q, Tu L, Tang C, Xu T, Deng L, et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 2012;46:131-141.
Zheng S, Chang S, Lu J, Chen Z, Xie L, Nie Y, He B, et al. Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS One 2011;6:e21064.
Khalil IA, Hayashi Y, Mizuno R, Harashima H. Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. J Control Release 2011;156:374-380.
Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 2007;27:696-722.
Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 2011;44:1094-1104.
Li Y, Zhu Y, Xia K, Sheng R, Jia L, Hou X, Xu Y, et al. Dendritic poly(L-lysine)-b-Poly(L-lactide)-b-dendritic poly(L-lysine) amphiphilic gene delivery vectors: roles of PLL dendritic generation and enhanced transgene efficacies via termini modification. Biomacromolecules 2009;10:2284-2293.
Byeon JH, Kim HK, Roberts JT. Monodisperse Poly(lactide-co-glycolic acid)-Based Nanocarriers for Gene Transfection. Macromol Rapid Commun 2012; 23:1821-1825.
Nogueira N, Conde O, Minones M, Trillo JM, Minones J, Jr. Characterization of poly(2-hydroxyethyl methacrylate) (PHEMA) contact lens using the Langmuir monolayer technique. J Colloid Interface Sci 2012;385:202-210.
So H, Lee J, Han SY, Oh HB. MALDI In-Source Decay Mass Spectrometry of Polyamidoamine Dendrimers. J Am Soc Mass Spectrometry 2012:DOI: 10.1007/s13361-13012-10445-13364.
Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012;161:188-197.
Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 2002;7:d717-725.
Alino SF, Benet M, Dasi F, Crespo J. Asialofetuin liposomes for receptor-mediated gene transfer into hepatic cells. Methods Enzymol 2003;373:399-421.
Alino SF, Herrero MJ, Noguera I, Dasi F, Sanchez M. Pig liver gene therapy by noninvasive interventionist catheterism. Gene Ther 2007;14:334-343.
Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv 2008;5:299-302.
Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 2011;55:838-845.
Hyodo I, Mizuno M, Yamada G, Tsuji T. Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. Liver 1993;13:80-85.
Sawamura T, Nakada H, Hazama H, Shiozaki Y, Sameshima Y, Tashiro Y. Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma. Gastroenterology 1984;87:1217-1221.
Dorasamy S, Narainpersad N, Singh M, Ariatti M. Novel targeted liposomes deliver siRNA to hepatocellular carcinoma cells in vitro. Chem Biol Drug Des 2012:10.1111/j.1747-0285.2012.01446.x.
Feng M, Cai Q, Shi X, Huang H, Zhou P, Guo X. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J Drug Targeting 2008;16:502-508.
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010;18:1357-1364.
Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000;35:665-672.
Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, Meijer DK, et al. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29:1486-1493.
Li F, Li QH, Wang JY, Zhan CY, Xie C, Lu WY. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release 2012;159:261-270.
Beljaars L, Olinga P, Molema G, de Bleser P, Geerts A, Groothuis GM, Meijer DK, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA). Liver 2001;21:320-328.
Li F, Song Z, Li Q, Wu J, Wang J, Xie C, Tu C, et al. Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin alphavbeta3 expression with SPECT in rat. Hepatology 2011;54:1020-1030.
Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008;26:431-442.
Yen RD, Zern MA, Wu J. Molecular therapy for hepatic fibrosis. Hauppauge, NY.: Nova Science Publishers, 2006: 1-23.
Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001;12:861-870.
Diez S, Navarro G, de ICT. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med 2009;11:38-45.
Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930-937.
Wu J, Liu L, Yen RD, Catana A, Nantz MH, Zern MA. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 2004;40:195-204.
He SQ, Zhang YH, Venugopal SK, Dicus CW, Perez RV, Ramsamooj R, Nantz MH, et al. Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. Liver Transpl 2006;12:1869-1879.
Wu J, Danielsson A, Zern MA. Toxicity of hepatotoxins: new insights into mechanisms and therapy. Expert Opin Investig Drugs 1999;8:585-607.
Wu J, Karlsson K, Danielsson A. Effects of vitamins E, C and catalase on bromobenzene- and hydrogen peroxide-induced intracellular oxidation and DNA single-strand breakage in Hep G2 cells. J Hepatol 1997;26:669-677.
Wu J, Karlsson K, Danielsson A. Protective effects of trolox C, vitamin C, and catalase on bromobenzene-induced damage to rat hepatocytes. Scand J Gastroenterol 1996;31:797-803.
Wu J, Soderbergh H, Karlsson K, Danielsson A. Protective effect of S-adenosyl-L-methionine on bromobenzene- and D-galactosamine-induced toxicity to isolated rat hepatocytes. Hepatology 1996;23:359-365.
Cui Y-Y, Qian J-M, Yao A-H, Ma Z-Y, Qian X-F, Zha X-M, Zhao Y, et al. SOD mimetic improves the function, growth, and survival of small-size liver grafts after transplantation in rats. Transplantation 2012; 94:687-694.
Qian JM, Zhang H, Wu XF, Li GQ, Chen XP, Wu J. Improvement of recipient survival after small size graft liver transplantation in rats with preischemic manipulation or administering antisense against nuclear factor-kappaB. Transplant Int 2007;20:784-789.
Liu PG, He SQ, Zhang YH, Wu J. Protective effects of apocynin and allopurinol on ischemia/reperfusion-induced liver injury in mice. World J Gastroenterol 2008;14:2832-2837.
Luedde T, Trautwein C. The role of oxidative stress and antioxidant treatment in liver surgery and transplantation. Liver Transpl 2006;12:1733-1735.
Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007;15:378-385.
Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ, Beaudet AL, et al. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 2007;15:732-740.
Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26:549-551.
Thiel C, Thiel K, Etspueler A, Morgalla MH, Rubitschek S, Schmid S, Steurer W, et al. A reproducible porcine model of acute liver failure induced by intrajejunal acetaminophen administration. Eur Surg Res 2011;46:118-126.